The results of the study may cut down on the number of unnecessary open-heart surgeries while also identifying and targeting those who are at highest risk and need it most.
Preliminary results from phase 1 study demonstrate a 46.7 percent overall response rate and 100 percent disease control rate with smart chemotherapy DS-8201 in a subgroup analysis of HER2-expressing metastatic breast cancer pre-treated with T-DM1 and pert